179. Clin Plast Surg. 2018 Jul;45(3):313-317. doi: 10.1016/j.cps.2018.03.003.Hormonal Management for Transfeminine Individuals.Abramowitz J(1), Tangpricha V(2).Author information: (1)Division of Endocrinology and Metabolism, Department of Medicine, UTSouthwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9302,USA. Electronic address: Jessica.Abramowitz@utsouthwestern.edu.(2)Division of Endocrinology, Metabolism & Lipids, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle NE-WMRB 1301, Atlanta, GA30322, USA.Transfeminine individuals are treated with estradiol and anti-androgen agents to transition to a more feminine appearance. The physical changes that occur withestradiol therapy include breast development, body fat redistribution, anddecreased muscle mass. Transfeminine treatment regimens require monitoring anddose adjustments to achieve appropriate physiologic targets to enhancefeminization and decrease risk of adverse outcomes. Adverse effects associatedwith estradiol use include thromboembolic disease, macroprolactinoma, breastcancer, coronary artery disease, cerebrovascular disease, cholelithiasis, andhypertriglyceridemia. Benefits of hormonal treatment may include both animprovement in quality of life and a decrease in gender dysphoria.Copyright Â© 2018 Elsevier Inc. All rights reserved.DOI: 10.1016/j.cps.2018.03.003 PMID: 29908618 